EBQ:CRASH-2 Trial: Difference between revisions

(Created page with "{{JC info | title= | abbreviation= | expansion= | published= | author= | journal= | year= | volume= | issue= | pages= | pmid= | fulltexturl= | pdfurl= }} ==Clinical ...")
 
No edit summary
Line 1: Line 1:
{{JC info
{{info
| title=  
| title=Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage
| abbreviation=  
| abbreviation=CRASH-2
| expansion=
| expansion=Clinical Randomisation of an Antifibrinolytic in Significant Hemorrhage 2
| published=  
| published=2010-07
| author=  
| author=Shakur H, et al
| journal=  
| journal=The Lancet
| year=  
| year=2010
| volume=  
| volume=376
| issue=
| issue=9734
| pages=  
| pages=23-32
| pmid=  
| pmid=20554319
| fulltexturl=  
| fulltexturl=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960835-5/fulltext
| pdfurl=
| pdfurl=http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673610608355.pdf
}}
==Clinical Question==
==Clinical Question==
   
   

Revision as of 02:52, 5 January 2014

{{info | title=Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage | abbreviation=CRASH-2 | expansion=Clinical Randomisation of an Antifibrinolytic in Significant Hemorrhage 2 | published=2010-07 | author=Shakur H, et al | journal=The Lancet | year=2010 | volume=376 | issue=9734 | pages=23-32 | pmid=20554319 | fulltexturl=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960835-5/fulltext | pdfurl=http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673610608355.pdf

Clinical Question

Conclusion

Major Points

Study Design

Inclusion Criteria

Exclusion Criteria

Interventions

Outcome

Primary Outcomes

Secondary Outcomes

Subgroup analysis

Criticisms & Further Discussion

Funding

Sources